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Abstract Public concern about the presence of natural and
anthropogenic compounds which affect human health by
modulating normal endocrine functions is continuously
growing. Fast and simple high-throughput screening methods
for the detection of hormone activities are thus indispens-
able. During the last two decades, a panel of different in vitro
assays has been developed, mainly for compounds with an
estrogenic mode of action. Here we describe the develop-
ment of an androgen transcription activation assay that is
easy to use in routine screening. Recombinant yeast cells
were constructed that express the human androgen receptor
and yeast enhanced green fluorescent protein (yEGFP), the
latter in response to androgens. Compared with other
reporters, the yEGFP reporter protein is very convenient
because it is directly measurable in intact living cells, i.e.,
cell wall disruption and the addition of a substrate are not
needed. When yeast was exposed to 17β-testosterone, the
concentration where half-maximal activation is reached
(EC50) was 50 nM. The relative androgenic potencies,
defined as the ratio between the EC50 of 17β-testosterone
and the EC50 of the compound, of 5α-dihydrotestosterone,
methyltrienolone, and 17β-boldenone are 2.3, 1.4, and 0.15
respectively. The results presented in this paper demonstrate
that this new yeast androgen bioassay is fast, sensitive, and
very specific and also suited to detect compounds that have
an antiandrogenic mode of action.
Keywords Antagonists . Brominated flame retardants .
Crosstalk .Metabolism . Receptor . Saccharomyces
cerevisiae
Introduction
There is concern that chemicals in our food, water, and
environment affect human health by disrupting normal
endocrine function, possibly leading to reproductive failure
in humans and tumors in sensitive tissues [1, 2]. This
relates to chemicals with previously unknown hormonal
properties, like certain pesticides and plasticizers, but also
to compounds used in pharmaceutical preparations, eg., oral
contraceptives and tablets for hormone-replacement thera-
py, the endogenous steroids excreted in urine of man and
domestic animals and potentially also compounds used for
their growth-promoting properties in animals. Of all
endocrine disruptors, environmental estrogens are the most
studied [3]. However, recent studies show a crucial
involvement of the androgen receptor in abnormal sex
development. The presence of pollutants with adverse
effects on human androgen receptor (hAR) has been
reported from paper-mill effluents and as a result of
intensive farming [4, 5]. Xenoandrogenic exposure-related
disorders include testicular cancer, hypospadias, cryptor-
chidism, and poor sperm and very recently prepubertal
gynecomastia was linked to both estrogenic and antiandro-
genic effects of lavender and tea tree oil [6].
Chemical and immunological methods are commonly
used to detect steroid hormones in food, clinical practice,
environmental samples, or doping control. Owing to the
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great variety of chemicals with hormonelike activity, these
methods have the drawback that they only quantify the
compound of interest and are not able to determine
biological activity of unknown compounds and their
metabolites, this in contrast to biological assays. Receptor-
based transcription activation assays can be used to detect
all compounds having affinity for a given receptor [7, 8]. In
contrast to receptor binding assays, receptor gene bioassays
also include the transactivation step and can distinguish
between receptor agonists and receptor antagonists [9]. This
feature is very helpful in detecting both known and
unknown compounds.
Several assays have been developed for this purpose,
using both mammalian and yeast cells. In general,
transcription activation assays based on mammalian, or
more particular human, cell lines have been shown to be
more sensitive than yeast-based assays, and may be able to
identify compounds that require human metabolism for
activation into their active state. Metabolic conversion can
either activate or inactivate some compounds [10], whereas
the relatively low metabolic capacity of yeast ensures that
the test reflects the activity of the original compound. In
addition, yeast-based assays have several other advantages.
These include low costs, easy handling, lack of known
endogenous receptors that may compete with the receptor
activity under investigation (no crosstalk), and the use of
media that are devoid of steroids [11–13]. Furthermore,
yeast cell assays are extremely robust and survive extracts
from dirty sample matrices such as sediments, urine, and
feed [14–16]. Especially in the case of androgens, the lack
of known endogenous receptors in yeast is a great
advantage compared with mammalian cell lines, as andro-
gen responsive elements (AREs) can also be activated by
the progesterone receptor and the glucocorticoid receptor.
To avoid potential crosstalk in mammalian cell lines, a lot
of efforts was expended to construct an ARE that is specific
and no longer inducible by the progesterone and glucocor-
ticoid receptor [17–19]. However, up till now such an ARE
does not exist and it is doubtful whether it will be found, as the
consensus progesterone responsive element/glucocorticoid
responsive element is equal to the consensus ARE. Moreover,
the glucocorticoid receptor is normally expressed in all
mammalian cell types. So far this has resulted in cell lines
that are not specific for androgens and that also respond to
gestagens or glucocorticoids [20–22].
This paper reports the development of a new yeast
androgen bioassay by creating a stably transfected yeast
strain that expresses yeast enhanced green fluorescent
protein (yEGFP) as a measurable reporter protein in
response to androgens. The lack of known endogenous
receptors in yeast enabled us to use the strong nonspecific
consensus ARE sequence, which is actually a common
hormone responsive element that is recognized by the
androgen, progesterone and glucocorticoid receptors and
can therefore not be used in mammalian cell lines
expressing more than one of these receptors. Exposures to
17β-testosterone, 17β-estradiol, progesterone, dexametha-
sone, and other compounds were performed in 96-well
plates in order to demonstrate the suitability and specificity
of this new yeast androgen bioassay. Additionally, fluta-
mide and several brominated flame retardants were tested
for their antagonistic mode of action and the results were
compared with a yeast androgen bioassay expressing β-
galactosidase as a reporter protein.
Materials and methods
Chemicals
Chemicals and methods to prepare the growth media, to
perform PCR, to isolate DNA, and to transform bacteria and
yeast were as described earlier [23]. Corticosterone, dexa-
methasone, 17α-estradiol, 17β-estradiol, estrone, flutamide,
4-hydroxytamoxifen, medroxyprogesterone 17-acetate, and
progesterone were obtained from Sigma (St. Louis, MO,
USA). The following compounds were obtained from
Steraloids (Newport, RI, USA): 17β-boldenone, diethylstil-
bestrol, 5α-dihydrotestosterone, 17α-ethynylestradiol, 17β-
testosterone and 17β-trenbolone. Tetrahydrogestrinone
(THG) was a gift from M. Thevis (DSHS, Cologne,
Germany). Copper sulfate and dimethyl sulfoxide (DMSO)
were obtained from Merck (Darmstadt, Germany) and
methyltrienolone was obtained from PerkinElmer (USA).
All restriction endonucleases and corresponding buffers
were obtained from New England Biolabs (Hitchin, UK)
and the yeast β-galactosidase assay kit was from Pierce
Biotechnology (Rockford, IL, USA). 2,4,6-Tribromophenol
(TBP), BDE-39, and the hydroxyl derivative 4-OH-BDE-17
were synthesized at the Wallenberg Laboratory (Stockholm
University, Sweden).
Yeast strains
The yeast Saccharomyces cerevisiae (CEN.PK 102-5B,
K20, URA3−, HIS3−, LEU−) host strain was a gift from H.
Silljé (University of Utrecht, The Netherlands). The yeast
androgen bioassay with β-galactosidase as a marker was
kindly provided by D.P. McDonnell (Duke University, USA).
Plasmids
The p403-GPD and p406-CYC1 yeast expression vectors
were obtained from the American Type Culture Collection
(ATCC, Rockville, Maryland, USA). The pyEGFP3 plasmid
was a gift from A.J. Brown (Stanford University, USA).
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Construction of the p403-GPD-hAR expression vector
The yeast cells provided by McDonnell were grown
overnight and chromosomal DNA was isolated. This DNA
was used to serve as a template for the PCR to obtain the
complementary DNA (cDNA) of hAR. Full-length hAR
cDNA was obtained using the Expand High Fidelity PCR
system (Boehringer Mannheim) and an Eppendorf Master-
cycler gradient. The sequence of the 5′-primer was 5′-
GCTCTAGAATGGAAGTGCAGTTAGGGCTGGG-3′,
containing a restriction site for XbaI just before the ATG
start codon. The sequence of the 3′-primer was 5′-
GCGGATCCTCACTGGGTGTGGAAATAGATGGG-3′,
containing a restriction site for BamHI just after the TGA
stop codon. This PCR generated a full-length double-
stranded (ds) cDNA of 2,763 bp of the hAR gene with a 5′-
XbaI and a 3′-BamHI restriction site.
The 2,763-bp full-length hAR PCR product was isolated
from a 1% low-melt agarose gel, cleaved with XbaI and
BamHI and ligated into the corresponding site of the p403-
GPD yeast vector. Plasmid digestion and PCR controls
revealed several good clones.
Construction of the p406-ARE2-CYC1-yEGFP reporter vector
A set of complementary oligonucleotides (a and b), each
with two consensus ARE sequences (in bold), were
synthesized. A solution with both cDNA oligonucleotides,
2.5 μM of each, was heated at 95 °C and cooled down to
room temperature in 2 h. This set gave a ds DNAwith a 5′-
SacI sticky end and a 3′-MscI blunt end.Sa: 5′-AAAGTC
AGAACAGCATGTTCTGATCAAATCTAGAAGATC
CAAAGTCAGAACAGCATGTTCTGATCAAACTC
GAGCAGATC CG C CAGGCG TG TATATATA
GCGTGGATGG-3′Sb: 5′-CCATCCACGCTATATATA
CACGCCTGGCGGATCTGCTCGAGTTTGATCAGAA
CATGCTGTTCTGACTTTGGATCTTCTAGATTTGAT
CAGAACATGCTGTTCTGACTTTAGCT-3′.
This ds DNA was cloned into the corresponding site of
the p406-CYC1 vector. Subsequently, yEGFP [24] obtained
from a HindIII/SalI double digestion of pyEGFP was
cloned in the corresponding HindIII/SalI sites of the
p406-ARE2-CYC1 reporter construct. Plasmid digestion
and PCR controls revealed several good clones.
Transformation of yeast cells
Transformation of yeast K20 host strain (Ura−, His−, and
Leu−) was performed by the lithium acetate protocol as
described earlier [23]. First, the yeast was transformed with
the p406-ARE2-CYC1-yEGFP reporter vector, integrated at
the chromosomal location of the uracil gene via homolo-
gous recombination. Therefore, prior to transformation, the
reporter vector was linearized by cutting with StuI, which
has a unique restriction site in the URA3 marker gene.
Transformants were grown on minimal medium plates
containing L-leucine and L-histidine (MM/L plates). This
yeast reporter strain was then transformed with the p403-
GPD-hAR expression vector, which was linearized by
cleavage with NsiI, which has a unique restriction site in
the HIS3 marker gene (histidine). Transformants were
grown on MM/L plates and PCR controls were used to
select clones that contain the p406-ARE2-CYC1-yEGFP
reporter and the p403-GPD-hAR expression construct.
PCR controls
PCR controls were performed on the reporter-receptor
transformants. Yeast chromosomal DNA of transformants
was isolated and PCR controls were performed. PCR I was
performed with a 5′-primer on the backbone of the reporter
plasmid and a 3′-primer on the ARE2 sequence. The
sequence of the 5′-primer was 5′-AGCGAGTCAGT-
GAGCGAGGAAG-3′ and the sequence of the 3′-primer
was 5′-TGCTGTTCTGACTTTGGATC-3′. PCR II was
performed with a 5′-primer on the CYC1 (cytochrome c
oxidase) promoter of the reporter plasmid and a 3′-primer
on the CYC1 terminator. The sequence of the 5′-primer was
5′-TCTATAGACACACAAACACAA-3′ and the sequence
of the 3′-primer was 5′-GGGAGGGCGTGAATGTAAG-3′.
PCR III was performed with the primers that were also used
to obtain the full length cDNA of the hAR (see “Construc-
tion of the p403-GPD-hAR expression vector”).
Streamlined yEGFP assay with the yeast androgen bioassay
The day before running the assay, a single colony from a
MM/L agar plate was used to inoculate 10 mL of the
selective MM/L medium. This culture was grown overnight
at 30 °C with vigorous orbital shaking. At the late log
phase, the yeast androgen receptor biosensor was diluted in
the selective MM/L medium to an optical density (OD) at
604 nm between 0.08 and 0.12. For exposure, aliquots of
200 μL of this diluted yeast culture were pipetted into each
well of a 96-well plate and 2 μL of a 17β-testosterone or
other stock solution in DMSO was added. DMSO-only
controls were included in each experiment and each sample
concentration was assayed in triplicate. Exposure was
performed for 24 h at 30 °C and orbital shaking at
125 rpm. Fluorescence was measured at 0 and 24 h directly
in a CytoFluor multiwell plate reader (Series 4000,
PerSeptive Biosystems) using excitation at 485 nm and
measuring emission at 530 nm. The fluorescence signal was
corrected with the signals obtained with MM/L containing
DMSO solvent only. Densities of the yeast culture were
determined by measuring the OD at 630 nm, but this
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was only done to check whether a sample was toxic for
the yeast cells. For the calculation of the relative androgenic
potency (RAP) of the compounds in the yeast an<
drogen bioassay, the data of a complete dose–response
curve were fitted using the equation y ¼ a0= 1þ x=a1ð Þa2½ 
(Slide write Plus, version 6.00). This is equivalent to
response ¼ max imum response  minumum response=
1þ agonist½ =ð½ EC50Þwidth of transition, where response is the
measured fluorescence signal, [agonist] is the concentration
of the test compound, and EC50 is the concentration of the
test compound giving half-maximum response.
lacZ-based yeast androgen bioassay: β-galactosidase assay
An agar plate containing the selective growth medium,
consisting of a yeast nitrogen base with dextrose (2%),
lysine (36 mg/L), tryptophan (48 mg/L), uracil (24 mg/L),
and adenine (41 mg/L), was inoculated with the yeast
androgen receptor cytosensor from a frozen -80 °C stock
(20% glycerol v/v). The plate was incubated at 30 °C for
24–48 h and then stored at 4 °C. The day before running
the assay, a single colony of the yeast was used to inoculate
10 mL of the selective growth medium. This culture was
grown overnight at 30 °C with vigorous orbital shaking at
225 rpm. At the late log phase, the yeast androgen receptor
cytosensor was diluted in growth medium to an OD of 0.06
at 604 nm, and CuSO4 (0.05 mM) was added to induce the
expression of the hAR. For exposure in 96-well plates,
aliquots of 200 μL of this diluted yeast culture were pipetted
into each well and 2 μL of stock solutions in DMSO was
added. Exposure was performed for 24 h at 30 °C and
125 rpm, and the β-galactosidase activity was measured with
a commercial yeast β-galactosidase assay kit from Pierce
(Rockford, IL, USA). This kit uses o-nitrophenyl β-
D-galactopyranoside as a substrate, and the solution turns
yellow upon hydrolysis of β-D-galactopyranoside to o-
nitrophenol and galactose. The yellow o-nitrophenol is
measured in a Biotek (Winooski, VT, USA) model ELx
808 series ultra microplate reader at 405 nm. Densities of the
yeast culture were determined by measuring the OD at
630 nm. The measured response at 405 nm was corrected for
the OD at 630 nm.
Results and discussion
A recombinant yeast cell was constructed that expresses the
hAR and yEGFP as a reporter protein in response to
androgens. Both the receptor construct as well as the
reporter construct were stably integrated into the yeast
genome by the use of yeast-integrating plasmids. For the
construction of the reporter vector the p406-CYC1 plasmid,
containing the URA3 marker gene, was used. Two
consensus AREs were placed in the SacI/MscI site of the
truncated CYC1 promoter in a way that the −254 to −147
XhoI-SphI part of the CYC1 promoter was restored [23].
High expression levels of the androgen receptor were
obtained by placing the cDNA of the hAR gene behind
the strong constitutive yeast glyceraldehyde-3-phosphate
dehydrogenase (GPD) promoter in the p403-GPD plasmid.
This plasmid contains the HIS3 marker gene. Transfected
strains were checked with PCR. The correct and specific
functioning of the yeast androgen bioassay was studied by
exposures to 17β-testosterone and other compounds and the
results were compared with results obtained with the lacZ-
based yeast androgen bioassay provided by McDonnell. In
addition, the antiandrogenic properties of several brominat-
ed flame retardants were investigated.
PCR controls
A number of different PCR controls were carried out to
check the integration of the vectors into the yeast genome.
Figure 1 shows the gel electrophoresis results of these PCR
controls. PCR I (Fig. 1a) was performed with primers on
the backbone of the p406 plasmid and on the ARE2
sequence. As expected, it gave the specific 360-bp band
with the p406-ARE2-CYC1-yEGFP reporter vector and the
DNA that was isolated from the yeast androgen biosensor.
The negative controls, performed with the empty p406-
CYC1 plasmid and with the DNA that was isolated from the
empty yeast host (the nontransfected yeast cell), showed no
PCR bands. PCR II (Fig. 1a) was performed with primers
on the CYC1 promoter and the CYC1 terminator. As
expected, it gave the specific 873-bp band with the reporter
vector and the DNA that was isolated from the biosensor,
because both contain the reporter construct with the yEGFP
that was ligated between the CYC1 promoter and CYC1
terminator. The negative controls, performed with the
empty p406-CYC1 plasmid and with the DNA that was
isolated from the empty yeast host, did not show the
reporter-specific 873-bp band. However, this PCR generat-
ed a 435-bp band with the DNA of the empty yeast host
and the biosensor. This 435-bp band corresponds to the
CYC gene of the yeast host itself and is therefore also a
specific band. PCR III (Fig. 1b) was performed with the
primers on the hAR gene. As expected, it gave the specific
2,763-bp band with the p403-GPD-hAR expression vector
and the DNA that was isolated from the biosensor. In the
negative control, performed with the DNA that was isolated
from the yeast host, the receptor-specific 2,763-bp band
was not present. These PCR controls demonstrate that all
specific PCR bands can be seen, thus demonstrating that
our yeast androgen bioassay contains the p403-GPD-hAR
expression vector and the p406-ARE2-CYC1-yEGFP re-
porter vector, both stably integrated in the yeast genome.
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Dose–response curves obtained with the new yeast
androgen bioassay
The dose–response curves for several natural and synthetic
androgens are shown in Fig. 2. 5α-Dihydrotestosterone,
17β-testosterone and 17β-boldenone caused a dose-related
increase in the production of yEGFP, demonstrating that
these compounds are potent androgens. The bioassay
showed a limit of detection of 3 nM for 5α-dihydrotestos-
terone with a dynamic range from 3 to 500 nM and very
low standard deviations (les than 3%). The figure also
shows that 17β-estradiol and progesterone give a response.
The female hormone 17β-estradiol gives a full dose–
response curve, but the maximum of the curve is reached
at a 500 times higher concentration than that of 17β-
testosterone and is less steep. Progesterone gives a
response, but the maximum response is only about 35%
of that of 17β-testosterone and is reached at a 25 times
higher concentration. Both 17β-estradiol and progesterone
are known to possess androgenic properties. Progesterone
displays low binding to the androgen receptor [25] and
shows androgenic effects in vivo [26]. According to [27],
17β-estradiol and progesterone showed androgenic activity
in ten out of 11 and seven out of nine mammalian cell
reporter gene (MCRG) systems, respectively. The cortico-
steroids corticosterone and dexamethasone showed no
response in our assay.
Table 1 shows the calculated EC50, ie., the concentration
giving a half-maximum response, and the RAP, defined as
the ratio between the EC50 of 17β-testosterone and the
EC50 of the compound, for several compounds. The yeast
androgen bioassay showed good sensitivity towards all
Fig. 1 PCR controls. The PCR controls were performed as described
in “PCR controls.” a Lanes 1, 6 and 11 contain a 100-bp ladder. PCR I
was performed with primers on the backbone of the p406 plasmid and
on the ARE2 sequence. Lanes 2–5 are PCR I on the p406-ARE2-
CYC1-yEGFP reporter vector, the DNA that was isolated from the
yeast transformant, the empty p406-CYC1 plasmid, and the DNA that
was isolated from the empty yeast host (the nontransfected yeast cells),
respectively. PCR II was performed with primers on the CYC1
promoter and the CYC1 terminator. Lanes 7–11 are PCR II on the
reporter vector, the DNA from the yeast transformant, the empty p406-
CYC1 plasmid, and the DNA from the empty yeast host respectively. b
Lane 1 contains a 1-kb ladder. PCR III was performed with the primers
on the human androgen receptor gene. Lanes 2–4 are PCR III on the
p403-GPD-hAR expression vector, the DNA from the yeast trans-
formant, and the DNA from the empty yeast host, respectively. yEGFP
yeast enhanced green fluorescent protein
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androgens tested, with the following range of potencies:
5α-dihydrotestosterone > 17β-trenbolone > methyltrieno-
lone > tetrahydrogestrinone > 17β-testosterone > 17β-
boldenone > medroxyprogesterone acetate > 17β-estradiol >
progesterone. Steroids representative for other hormone
receptors, like estrone, 17α-estradiol, 17α-ethynylestradiol,
and diethylstilbestrol for the estrogen receptor and cortico-
sterone and dexamethasone for the glucocorticoid receptor,
showed no agonistic response. Only 17β-estradiol, proges-
terone and medroxyprogesterone acetate gave a clear
agonistic response. However, these compounds are known
to exert androgenic effects.
Compared with the NIH publication [27], there are a few
discrepancies. According to [27], estrone is an androgen
receptor agonist that showed androgenic activity in two out
of two MCRG systems. However, some mammalian cells
are able to convert estrone into 17β-estradiol and vice
versa. This conversion is ascribed to 17β-hydroxysteroid
dehydrogenase 3 and this enzyme is responsible for the
high relative estrogenic potency (REP) of estrone in the
estrogen bioassay with the T47-D breast cancer cells (ER-
CALUX test). In that test, the estrogenic potency of estrone
was equal to that of 17β-estradiol and a REP of 1.0 was
reported for estrone [10]. This probably explains why
estrone gave a positive result for androgenic activity in two
MCRG systems, but gave a negative result in our yeast
androgen bioassay. Yeast is obviously not able to convert
estrone into 17β-estradiol. The reported REP of 0.2 in our
yeast estrogen biosensor corresponds nicely with the in
vivo potency of this compound [28]. Dexamethasone was
also described as an androgen receptor agonist in the NIH
publication, showing androgenic activity in three out of
four mammalian assays, but gave a negative result in our
yeast androgen bioassay. However, these MCRG systems
use an MMTV-Luc reporter construct or an ARE-Luc
reporter construct. Both the MMTV and the ARE sequence
are recognized by the glucocorticoid receptor and this
means that the response found in these MCRG systems is
probably due to crosstalk, as the glucocorticoid receptor is
normally expressed in all cell types.
Dose–response curves obtained with the lacZ-based yeast
androgen bioassay
Figure 3 shows the dose–response curves for several natural
and synthetic androgens obtained with the lacZ-based yeast
androgen bioassay. The assay was simplified in our
laboratory by scaling it down to a 96-well format and the
use of a β-galactosidase assay kit. With increasing β-
galactosidase activity, the density of the yeast culture,
measured at 630 nm, dropped to about 50% (data not
shown). Therefore, the measured â-galactosidase activity
was corrected for the OD of the yeast culture. Table 2
shows the calculated EC50 and the corresponding RAP
values. The data demonstrate that there is a good
correlation between the EC50 values for androgens deter-
mined in our laboratory and those reported by Gaido et al.
[29] in 1997. It seems that the lacZ-based yeast androgen
Fig. 2 Response of the yeast androgen biosensor to different
substances. Exposure to 17β-testosterone, 5α-dihydrotestosterone,
progesterone, dexamethasone, 17β-estradiol, and 17β-boldenone was
started by adding to 200 μL of a yeast culture a 2-μL aliquot of a stock
solution of the compound in dimethyl sulfoxide (DMSO). Fluores-
cence was determined after 24 h as described in “Streamlined yEGFP
assay with the yeast androgen bioassay.” Fluorescence signals are the
mean of a triplicate with the standard deviation (SD). 17β-T 17β-
testosterone, DHT 5α-dihydrotestosterone, Prog progesterone, Dex
dexamethasone, 17β-E2 17β-estradiol, Bold 17β-boldenone
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Table 1 EC50 concentrations and relative androgenic potencies (RAP) of compounds in the yeast androgen biosensor expressing yeast enhanced
green fluorescent protein in response to androgens
Compound Qualitative response
for AR agonisma
Commentsb EC50 (nM) in the yeast
androgen bioassayc
RAPd
17β-Testosterone Positive (11/11) Strong AR agonist 76 1.0
5α-Dihydrotestosterone Positive (21/21) Strong AR agonist, weak ER agonist 33 2.3
17β-Boldenone 510 0.15
17β-Trenbolone Positive Binds strongly to AR 52 1.5
Methyltrienolone Positive (8/8) AR agonist 54 1.4
Tetrahydrogestrinone AR agonist 65 1.2
17β-Estradiol Positive (10/11) AR agonist and antagonist, strong ER agonist 9,000 0.0084
Estrone Positive (2/2) AR agonist, strong ER agonist NR NR
17α-Estradiol Negative (1/1) ER agonist NR NR
17α-Ethynylestradiol Negative (1/1) Strong ER agonist NR NR
Diethylstilbestrol Negative (2/2) Strong ER agonist NR NR
4-Hydroxytamoxifene Negative (1/1) ER antagonist NR NR
Progesteronef Positive (7/9) 1,700 0.045
Medroxyprogesterone acetate Positive (4/4) Weak AR agonist 1,500 0.051
Corticosterone Negative (1/1) Binds weakly to AR NR NR
Dexamethasone Positive (3/4) AR agonist NR NR
Flutamide Negative (5/5) AR antagonist NR NR
2,4,6-Tribromophenol NR NR
BDE-19 NR NR
4-OH-BDE-17 NR NR
AR androgen receptor, ER estrogen receptor, NR no response
a Qualitative response for AR agonism across all mammalian cell reporter gene studies (data obtained from [27])
b Comments obtained from [27]
c The EC50 is the concentration giving half-maximum response.
d The RAP is defined as the ratio between the EC50 of 17β-testosterone and the EC50 of the compound.
e This compound was toxic to yeast above 30 μM.
f These compounds reach a maximum response that is lower than 70% of the maximum response obtained with 17β-testosterone. The maxima
obtained with 4-androstenedione and progesterone are about 40 and 35%, respectively.
Fig. 3 Response of the McDonnell yeast androgen bioassay to different
substances. Exposure to 17β-testosterone, 5α-dihydrotestosterone, proges-
terone, dexamethasone, 17β-estradiol, and 17β-boldenone was started by
adding to 200 μL of a yeast culture a 2-μL aliquot of a stock solution of
the compound in DMSO. The β-galactosidase activity was determined
after 24 h and corrected for the optical density at 630 nm as described in
“lacZ-based yeast androgen bioassay: β-galactosidase assay.” Signals are
the mean of a triplicate with the SD
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bioassay, in terms of EC50 values, is 5–10 times more
sensitive than our new bioassay. However, there was almost
no difference in the limit of detection. Although the curves
in the β-galactosidase assay go up at around 0.3 nM and in
the yEGFP assay at around 1 nM, the limit of detection is
about 3 nM for 5α-dihydrotestosterone in both assay types.
This is mainly because the standard deviations are much
higher in the β-galactosidase assay. However, the curves in
the β-galactosidase assay are much steeper and are thus
responsible for the lower EC50 values. The steeper curves
are probably due to using an enzyme as a marker, β-
galactosidase compared with a yEGFP marker protein, and
the expression of the RSP5 cofactor that enhances
transcription activation in the lacZ-based yeast androgen
bioassay. The dynamic range for 5α-dihydrotestosterone in
the McDonnell assay was from 3 to 100 nM and is slightly
smaller than the range of the new bioassay (3–500 nM).
There were also no great differences in the RAP values
determined, although methyltrienolone was more potent in
the lacZ-based bioassay. However, the new yEGFP bioas-
say is less sensitive for 17β-estradiol and progesterone:
RAPs of 0.008 and 0.045, respectively, and for the latter no
full dose–response curve, compared with RAPs of 0.1 and
0.068 and full dose–response curves in the lacZ-based
bioassay. This means that our new bioassay is more specific
for detecting compounds with a pure androgenic mode of
action. The main difference between the lacZ-based and our
yEGFP biosassay is that protein RSP5, which is a
counterpart of the mammalian RPF1, is overexpressed in
the lacZ-based bioassay in order to enhance transcriptional
efficacy. However, this cannot explain the observed
difference with methyltrienolone , as according to Imhof
and McDonnell [30], this did not alter the potency or
specificity of the assay. In addition and in contrast to the
lacZ-based yeast androgen bioassay there were no differ-
ences in the density of the yeast culture measured at
630 nm upon exposure to different compounds that induced
Table 2 EC50 concentrations and RAPs of compounds in the yeast
androgen bioassay expressing β-galactosidase in response to androgens
Compound EC50 (nM)
a by
Gaido et al. [29]
EC50 (nM)
b in
our laboratory
RAP
17β-Testosterone 4.7 11.5 1.0
5α-Dihydrotestosterone 3.5 4.9 2.3
17β-Boldenone ND 70 0.2
17β-Trenbolone ND 13 0.9
Methyltrienolone ND 3.7 3.1
Tetrahydrogestrinone ND 11.5 1.0
17β-Estradiol 86.1 95 0.1
17α-Estradiol ND NR NR
Progesterone 89.3 170 0.068
Corticosterone ND NR NR
Dexamethasone ND NR NR
ND not determined
a Values obtained by Gaido et al. [29], using the McDonnell yeast
androgen bioassay
b Values determined in our laboratory, using the McDonnell yeast
androgen bioassay (see “Dose–response curves obtained with the
lacZ-based yeast androgen bioassay”)
Fig. 4 Inhibition of a submaximal response obtained by 5α-dihydrotes-
tosterone with flutamide and three brominated flame retardants (BFRs).
Coexposure to a concentration of 5α-dihydrotestosterone that induced a
submaximal response was started by adding to 200 μL of a yeast culture,
1 μL of a 5α-dihydrotestosterone and 1 μL of the BFR stock solution in
DMSO. Fluorescence was determined after 24 h as described in
“Streamlined yEGFP assay with the yeast androgen bioassay.” Fluores-
cence signals are the mean of a triplicate with the SD. TBP 2,4,6-
tribromophenol
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yEGFP expression, which indicates a decreased growth of
yeast cells exposed to androgens in the lacZ-based yeast
androgen bioassay. The only other known yeast androgen
bioassay, one that uses luciferase as a reporter protein,
displays similar characteristics in terms of specificity and
was 5–10 times more sensitive in terms of EC50 values
[15]. However, this assay needs the correction of the same
yeast strain that only and stably expressed luciferase as an
external control to correct for and normalize the aspecific
responses caused by variation in cell vitality due to matrix
and analyte toxicity. Unorrected dose–response curves for
17β-testosterone displayed more than 10 times higher EC50
values. An earlier assay described by Lee et al. [31] in 2003
uses β-galactosidase, but only expresses the hinge-ligand
binding domain of the androgen receptor.
Antiandrogenic activity
The specificity of the new yeast androgen bioassay was
further demonstrated by the ability of antiandrogens to
suppress the induction of yEGFP. Figure 4 shows the
antiandrogenic activity of the known antagonist flutamide
and three brominated flame retardants, BDE-39, TBP, and
4-OH-BDE-17. The antagonistic properties were examined
by coexposure with a concentration of 5α-dihydrotestoster-
one that induced a submaximal response (50 nM). None of
these four compounds were able to show an agonistic
response (Table 1), but Fig. 4 clearly shows that all three
were able to inhibit the response induced by 5α-dihydro-
testosterone . The IC50 value was about 1 μM for flutamide,
and TBP and 4-OH-BDE-17 were about as potent, while
BDE-39 was clearly less antiandrogenic. Similar results
were obtained with a human cell line. Only TBP was less
potent in that test, but cytotoxicity of TBP could not be
excluded [32].
Conclusions
A recombinant yeast cell was constructed that expresses the
hAR and yEGFP as a reporter protein in response to
androgens. Compared with other yeast androgen bioassays,
this new biosassay showed a similar limit of detection and
dynamic range. However, the measurement of the fluores-
cence (yEGFP) can be followed as a function of incubation
time and is easier, quicker, and cheaper than the measure-
ment of the β-galactosidase or the luciferase activity, which
needs cell wall disruption and/or the addition of expensive
substrates. Owing to the ease of the yEGFP measurement,
standard deviations are generally less than 3%. Moreover,
the assay seems to be more robust and more specific for
detecting compounds with a pure androgenic mode of
action.
Brominated flame retardants with suspected antiandro-
genic properties were able to inhibit the response obtained
with 5α-dihydrotestosterone, the most potent endogenous
androgen, demonstrating that this yeast androgen bioassay
is suited to detect compounds with both agonistic and
antagonistic characteristics.
As all compounds tested were able to show either their
agonistic or their antagonistic properties, neither the cell
wall nor the cell membrane seemed to be an obstacle. As
for the yeast estrogen bioassay, we validated this new yeast
androgen bioassay according to international criteria, eg.,
the determination of the decision limit (CCα) and the
detection capability (CCβ). The decision limit is then used
to distinguish negative and suspect samples [16] (unpub-
lished results). The assay was proven to be useful to detect
the new designer steroid tetrahydrogestrinone in human
urine [33] while prohormones with an androgenic mode of
action, e.g., dehydroepiandrosterone, are not active in
yeast-based bioassays and need metabolic activation before
they can be detected [34]. Future work will include the
validation of the assay for urine and feed and the screening
of prohormones with and without metabolic activation. To
mimic the in vivo metabolic activation, liver slices, liver
cell lines, liver S9 enzymes, and pure enzymes will be used.
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